Portland, OR, Dec. 02, 2022 (GLOBE NEWSWIRE) — A new business intelligence report published by Allied Market Research, the global tumor ablation market was US$1.3 billion in 2021 and is estimated to reach US$4.7 billion by 2031, growing at a CAGR of 13.6% from 2022 to 2031.

Download free sample report:

Report coverage and details: https://www.alliedmarketresearch.com/request-sample/17626

Covid-19 scenario:

• The overall impact of the COVID-19 pandemic has affected key players in the tumor ablation market industry. However, the market is expected to recover in 2021 and beyond and show stable growth for the tumor ablation market in the coming future.
• Several patients postponed their surgeries to curb the spread of the virus, which negatively impacted the market.

The report segments the global tumor ablation market by technology, treatment, application, and region.

Depending on the type, the surgical ablation segment had the largest share in 2021, accounting for around two-fifths of the market. However, the percutaneous ablation segment is forecast to register the highest CAGR of 14.0% during the forecast period.

On the basis of application, Liver Cancer segment held the lion’s share in 2021, contributing about one-third of the market. However, it is estimated that the renal cancer segment will have the highest CAGR of 15.5% from 2021 to 2030.

Based on technology, the microwave ablation segment is expected to register the highest CAGR of 14.7% during the forecast period. But the other ablation…